Autolus Therapeutics (AUTL) Common Equity (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Common Equity for 9 consecutive years, with $178.1 million the latest figure, recorded in Q4 2025.

• Quarterly Common Equity fell 58.32% year-over-year to $178.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $178.1 million (down 58.32% YoY) and the FY2025 annual result came in at $178.1 million, down 58.32% from the prior year.
• Common Equity retreated to $178.1 million in Q4 2025 per AUTL's latest filing, from $265.5 million in the prior quarter.
• Over the last five years, Common Equity for AUTL reached as high as $582.0 million in Q1 2024 and fell as low as $111.5 million in Q4 2023.
• A 5-year average of $302.5 million and a median of $277.4 million in 2021 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity slumped 62.68% — and 2024, when it soared 283.34%.
• Year by year, Common Equity stood at $313.3 million in 2021, then declined by 4.67% to $298.7 million in 2022, then sank by 62.68% to $111.5 million in 2023, then surged by 283.34% to $427.3 million in 2024, then slumped by 58.32% to $178.1 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $178.1 million, $265.5 million, and $346.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.